What is Roth Capital’s Forecast for Bio-Path Q1 Earnings?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) – Equities research analysts at Roth Capital raised their Q1 2025 earnings estimates for shares of Bio-Path in a report released on Sunday, March 30th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of ($0.38) per share for the quarter, up from their previous forecast of ($0.40). The consensus estimate for Bio-Path’s current full-year earnings is ($3.34) per share. Roth Capital also issued estimates for Bio-Path’s Q2 2025 earnings at ($0.33) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.39) EPS, FY2026 earnings at ($1.28) EPS and FY2027 earnings at ($1.24) EPS.

Separately, StockNews.com assumed coverage on shares of Bio-Path in a report on Wednesday, March 26th. They issued a “sell” rating on the stock.

Bio-Path Stock Up 3.2 %

NASDAQ:BPTH opened at $0.17 on Wednesday. Bio-Path has a twelve month low of $0.12 and a twelve month high of $7.67. The stock’s 50 day moving average price is $0.38 and its two-hundred day moving average price is $0.74.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.